| Purpose | (Clinical Focus: This value set focuses on medications used for feminization in transgender women. It captures various forms and dosages of estrogen medications commonly included in transfeminine hormone replacement therapy (HRT).),(Data Element Scope: This value set defines a specific category of medications within the broader context of gender-affirming hormone therapy. It focuses on estrogens, which are crucial for feminization by promoting breast development, regulating menstrual cycles (in some regimens), and influencing other physiological changes.),(Inclusion Criteria: The value set includes a wide range of commercially available estradiol products commonly used in transfeminine HRT:
Injectable estradiol cypionate and estradiol valerate in various dosages (2mg/ml, 5mg/ml, 10mg/ml, 20mg/ml, 40mg/ml)
Transdermal estradiol patches (delivering varying amounts per hour)
Topical estradiol gels in various concentrations (0.0006mg/mg, 0.001mg/mg) and applicator sizes (250mg, 500mg, 750mg, 1000mg, 1250mg)),(Exclusion Criteria: This value set excludes other medications used in transfeminine HRT, such as antiandrogens and progestins.
It does not capture information about the frequency of administration (e.g., daily, weekly) beyond what is included in the concept codes (e.g., patch worn for several days).
It excludes any medications not classified as estrogens.) |
FHIR